Jerusalem Venture Partners recorded four exits in Q1 2026, the clearest signal yet that venture capital is shifting from AI research funding to deployment-phase harvests.1 The exits span healthcare, fintech, and adjacent sectors where AI has moved from prototype to regulated production.
The headline deal: Covera Health merging with Medmo to form an end-to-end diagnostic imaging platform.1 The combined company integrates scheduling, imaging, and quality assurance into a single workflow—a deployment-ready AI stack, not a research project. JVP cited the deal as evidence of its ability to "identify, build, and scale category-defining companies" across key sectors.1
The pattern reflects a capital cycle turning. Funds deployed into enterprise AI infrastructure between 2018 and 2022 are now clearing. Recycled capital is rotating into operational AI entering regulated industries at scale—healthcare diagnostics, fintech credit models, automotive safety systems.
Automotive is absorbing a parallel deployment wave. Geely Auto sold 3,024,567 units in 2025, a 39% year-on-year increase, while embedding AI across its Comprehensive Safety System 2.0.2 The system moves beyond vehicle-centric hardware, connecting sensors to a People-Vehicle-Road-Cloud-Satellite network.2 Geely has also opened critical safety patents—including one-touch window-breaking technology and underbody battery protection—to industry peers, accelerating ecosystem-wide adoption.2
Two deployment timelines are diverging. Commodity AI applications—diagnostics assistants, fintech scoring layers, workflow automation—are shipping in H2 2026. Frontier physical-world systems, including robotics platforms, autonomous driving silicon, and nuclear-scale compute infrastructure, are running 12-30 months behind.
For allocators, the bifurcation creates distinct return profiles. Near-term exits flow from software-layer AI embedded in regulated workflows—the Covera-Medmo model. Longer-dated returns require capital-intensive physical infrastructure reaching production scale and regulatory clearance.
JVP's Q1 results confirm the first category is delivering.1 The deployment wave now entering healthcare and automotive is not speculative—it is the operational output of research cycles that closed years ago. The next rotation of freed capital is already moving toward the next regulated frontier: fintech infrastructure and autonomous system deployment at industrial scale.
